Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2003 4
2004 5
2005 1
2007 3
2008 3
2009 5
2010 3
2011 5
2012 4
2013 4
2014 2
2015 5
2016 12
2017 10
2018 6
2019 4
2020 12
2021 16
2022 11
2023 8
2024 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacological brain cytoprotection in acute ischaemic stroke - renewed hope in the reperfusion era.
Fisher M, Savitz SI. Fisher M, et al. Nat Rev Neurol. 2022 Apr;18(4):193-202. doi: 10.1038/s41582-021-00605-6. Epub 2022 Jan 25. Nat Rev Neurol. 2022. PMID: 35079135 Free PMC article. Review.
For over 40 years, attempts to develop treatments that protect neurons and other brain cells against the cellular and biochemical consequences of cerebral ischaemia in acute ischaemic stroke (AIS) have been unsuccessful. However, the advent of intravenous thr …
For over 40 years, attempts to develop treatments that protect neurons and other brain cells against the cellular and biochemical consequenc …
Emerging agents for the treatment and prevention of stroke: progress in clinical trials.
Safouris A, Magoufis G, Tsivgoulis G. Safouris A, et al. Expert Opin Investig Drugs. 2021 Oct;30(10):1025-1035. doi: 10.1080/13543784.2021.1985463. Epub 2021 Oct 13. Expert Opin Investig Drugs. 2021. PMID: 34555978 Review.
EXPERT OPINION: Current approaches in stroke treatment and stroke prevention have already transformed stroke care from a linear one-for-all treatment paradigm to a more individualized approach that targets specific patient subgroups with novel pharmaceutical …
EXPERT OPINION: Current approaches in stroke treatment and stroke prevention have already transformed stroke care from …
The future of neuroprotection in stroke.
Chamorro Á, Lo EH, Renú A, van Leyen K, Lyden PD. Chamorro Á, et al. J Neurol Neurosurg Psychiatry. 2021 Feb;92(2):129-135. doi: 10.1136/jnnp-2020-324283. Epub 2020 Nov 4. J Neurol Neurosurg Psychiatry. 2021. PMID: 33148815 Review.
Investigators acknowledge the limitations of rodent or non-human primate stroke models, hundreds of putative neuroprotectants have been evaluated in preclinical models, but not one has entered the clinical realm. ...At the bedside in the last 5 years, uric acid and neri …
Investigators acknowledge the limitations of rodent or non-human primate stroke models, hundreds of putative neuroprotectants have be …
PSD-95-like membrane associated guanylate kinases (PSD-MAGUKs) and synaptic plasticity.
Xu W. Xu W. Curr Opin Neurobiol. 2011 Apr;21(2):306-12. doi: 10.1016/j.conb.2011.03.001. Epub 2011 Mar 28. Curr Opin Neurobiol. 2011. PMID: 21450454 Free PMC article. Review.
Overwhelming data have shown that PSD-95-like membrane associated guanylate kinases (PSD-MAGUKs), a major family of scaffold proteins at glutamatergic synapses, regulate basal synaptic AMPAR function and trafficking. It is now clear that PSD-MAGUKs have multifaceted …
Overwhelming data have shown that PSD-95-like membrane associated guanylate kinases (PSD-MAGUKs), a major family of scaffold p …
PSD-95: An Effective Target for Stroke Therapy Using Neuroprotective Peptides.
Ugalde-Triviño L, Díaz-Guerra M. Ugalde-Triviño L, et al. Int J Mol Sci. 2021 Nov 22;22(22):12585. doi: 10.3390/ijms222212585. Int J Mol Sci. 2021. PMID: 34830481 Free PMC article. Review.
However, recent results have provided strong evidence that postsynaptic density protein-95 (PSD-95) can be exploited as an efficient target for stroke neuroprotection by strategies able to counteract excitotoxicity, a major mechanism of neuronal death …
However, recent results have provided strong evidence that postsynaptic density protein-95 (PSD-95) can be exploited as an eff …
Neuroprotection during Thrombectomy for Acute Ischemic Stroke: A Review of Future Therapies.
Dammavalam V, Lin S, Nessa S, Daksla N, Stefanowski K, Costa A, Bergese S. Dammavalam V, et al. Int J Mol Sci. 2024 Jan 10;25(2):891. doi: 10.3390/ijms25020891. Int J Mol Sci. 2024. PMID: 38255965 Free PMC article. Review.
Advances in multiple neuroprotective therapies, including uric acid, activated protein C, nerinetide, otaplimastat, imatinib, verapamil, butylphthalide, edaravone, nelonemdaz, ApTOLL, regional hypothermia, remote ischemic conditioning, normobaric oxygen, and especia …
Advances in multiple neuroprotective therapies, including uric acid, activated protein C, nerinetide, otaplimastat, imatinib, verapam …
Ischemic Stroke, Lessons from the Past towards Effective Preclinical Models.
Amado B, Melo L, Pinto R, Lobo A, Barros P, Gomes JR. Amado B, et al. Biomedicines. 2022 Oct 13;10(10):2561. doi: 10.3390/biomedicines10102561. Biomedicines. 2022. PMID: 36289822 Free PMC article. Review.
Ischemic stroke is a leading cause of death worldwide, mainly in western countries. So far, approved therapies rely on reperfusion of the affected brain area, by intravenous thrombolysis or mechanical thrombectomy. ...Recently, a brain-protective drug-nerinetide …
Ischemic stroke is a leading cause of death worldwide, mainly in western countries. So far, approved therapies rely on reperfu …
Tat-NR2B9c prevents excitotoxic neuronal superoxide production.
Chen Y, Brennan-Minnella AM, Sheth S, El-Benna J, Swanson RA. Chen Y, et al. J Cereb Blood Flow Metab. 2015 May;35(5):739-42. doi: 10.1038/jcbfm.2015.16. Epub 2015 Feb 11. J Cereb Blood Flow Metab. 2015. PMID: 25669908 Free PMC article.
The Tat-NR2B9c peptide has shown clinical efficacy as a neuroprotective agent in acute stroke. Tat-NR2B9c is designed to prevent nitric oxide (NO) production by preventing postsynaptic density protein 95 (PSD-95) binding to N-methy …
The Tat-NR2B9c peptide has shown clinical efficacy as a neuroprotective agent in acute stroke. Tat-NR2B9c …
Delayed Administration of Tat-HA-NR2B9c Promotes Recovery After Stroke in Rats.
Zhou HH, Tang Y, Zhang XY, Luo CX, Gao LY, Wu HY, Chang L, Zhu DY. Zhou HH, et al. Stroke. 2015 May;46(5):1352-8. doi: 10.1161/STROKEAHA.115.008886. Epub 2015 Apr 7. Stroke. 2015. Retraction in: Stroke. 2020 Apr;51(4):e72. doi: 10.1161/STR.0000000000000224. PMID: 25851770 Retracted.
BACKGROUND AND PURPOSE: Previous studies reported that Tat-NR2B9c, a peptide disrupting the N-methyl-d-aspartate receptor-postsynaptic density protein-95 interaction, reduced ischemic damage in the acute phase after stroke. ...The aim of this study is …
BACKGROUND AND PURPOSE: Previous studies reported that Tat-NR2B9c, a peptide disrupting the N-methyl-d-aspartate receptor-post …
114 results